Mary Thwaites
YOU?
Author Swipe
View article: P-1072. Evaluation of the Spontaneous Mutation Frequencies of SPR719 Alone and in Combination with Other Agents Used to Treat <i>Mycobacterium avium</i> Complex Pulmonary Disease
P-1072. Evaluation of the Spontaneous Mutation Frequencies of SPR719 Alone and in Combination with Other Agents Used to Treat <i>Mycobacterium avium</i> Complex Pulmonary Disease Open
Background SPR720 (fobrepodacin), a novel oral benzimidazole prodrug that inhibits the ATPase activity of mycobacterial DNA gyrase B, is being developed for treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD). SPR719, the …
View article: 1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum
1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum Open
Antibacterial resistance continues its devastation of available therapies. Novel bacterial topoisomerase inhibitors (NBTIs) offer one solution to this critical issue. Two series of amine NBTIs bearing tricyclic DNA-binding moieties as well…
View article: Potent LpxC Inhibitors with <i>In Vitro</i> Activity against Multidrug-Resistant Pseudomonas aeruginosa
Potent LpxC Inhibitors with <i>In Vitro</i> Activity against Multidrug-Resistant Pseudomonas aeruginosa Open
New drugs with novel mechanisms of resistance are desperately needed to address both community and nosocomial infections due to Gram-negative bacteria. One such potential target is LpxC, an essential enzyme that catalyzes the first committ…
View article: Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae
Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae Open
Plazomicin is a next-generation aminoglycoside that was approved by the US FDA in June 2018 for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis due to Escherichia coli, Klebsiella pneumoniae, Enterob…
View article: Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae
Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae Open
The next-generation aminoglycoside plazomicin, in development for infections due to multidrug-resistant (MDR) Enterobacteriaceae , was evaluated alongside comparators for bactericidal activity in minimum bactericidal concentration (MBC) an…